BioPharma Resources

Drug Trial Radar · NCT06186804

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

A Multicenter, Single-arm, Open-label, Phase II Clinical Study. This Study Consisting of Part A and Part B to Evaluate the Efficacy and Safety of ABSK021 (Pimicotinib) in Patients With Chronic Graft Versus Host Disease

Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

64

Planned (sponsor's estimate)

Start

May 30, 2023

Primary completion

Oct 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Jan 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.

Conditions

  • cGvHD

Interventions

  • ABSK021Drug

    Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limited toxicity (DLT) at each dose can assess the incidence of DLT in patients during the observation period of DLT (Part A only)Time frame: Starting from the first medication, observe for 31 days
  2. Overall response rate after 6 cycles of treatmentTime frame: 6 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of the Army Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Guangdong Provincial Peoplep's Hospital

    Guangzhou, Guangdong, China

  • ZhuJiang Hospital of Southern Medical University

    Zhujiang, Guangdong, China

  • Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Fir St Affiliated Hospital,Zhejiang Univer Sity School of Medicine

    Hangzhou, Jiangsu, China

  • The First affiliated hospital of SuZhou University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Hematology Hospital of Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The First Teaching Hospital of Xinjiang Medical University

    Xinjiang, Xinjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.